Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
Real-world clinical outcomes in patients with mTNBC in the United States remain poor, particularly for patients with PD-L1-negative disease. There is an unmet need for more effective treatments for mTNBC.
Authors
- Tiffany A. Traina (ORCID: https://orcid.org/0000-0003-3597-0050)
- Sam Hillman
- Chintal H. Shah (ORCID: https://orcid.org/0000-0002-0225-507X)
- Simon M. Collin (ORCID: https://orcid.org/0000-0002-1239-1681)
- Manali Bhave
- Reema Tank
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1200/op-25-00822
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00